Consensus Glaukos Corporation

Stocks

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 15:33:03 2026-09-11 EDT			5-day change	1st Jan Change
167.45 ^USD	-1.72%		-6.01%	+47.73%

09-02	Glaukos Insider Sold Shares Worth $2,483,104, According to a Recent SEC Filing	MT
08-14	Glaukos Insider Sold Shares Worth $10,784,659, According to a Recent SEC Filing	MT

Evolution of the Average Target: Glaukos Corporation

Evolution of the Target Price: Glaukos Corporation

Changes in Analyst Recommendations: Glaukos Corporation

6d4f84031.6LTaBGUYdRkcCmd8UfhokcOYt3y3dn31zIlwOWEIhPM.rYHqPDRROE1DOjBFNowvo_qq4DvkEzCnn_FBTidJtbzfgLJwVHIBdnc-DA~4842a46fd6247497566ba3f0d9b8d9a2

Analysts' recommendations: Glaukos Corporation

07-30	HC Wainwrights Adjusts Glaukos Price Target to $195 From $168, Maintains Buy Rating	MT
07-30	UBS Adjusts Price Target on Glaukos Corp to $172 From $150, Maintains Neutral Rating	MT
07-30	Truist Raises Price Target on Glaukos to $215 From $180, Keeps Buy Rating	MT
07-30	Needham Raises Price Target on Glaukos to $201 From $150, Keeps Buy Rating	MT
07-28	UBS Downgrades Glaukos to Neutral From Buy, $150 Price Target	MT
07-16	Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating	MT
06-17	Needham Raises Price Target on Glaukos to $150 From $136, Keeps Buy Rating	MT
04-30	Truist Raises Price Target on Glaukos to $160 From $145, Keeps Buy Rating	MT
04-30	Needham Raises Price Target on Glaukos to $136 From $127, Keeps Buy Rating	MT
12-18	Truist Securities Adjusts Price Target on Glaukos Corp to $145 From $120, Maintains Buy Rating	MT
12-09	Needham Adjusts Glaukos Price Target to $125 From $117, Maintains Buy Rating	MT
25-10-27	Wells Fargo Upgrades Glaukos Corp to Overweight From Equalweight, Adjusts Price Target to $120 From $92	MT
25-09-22	Truist Trims Price Target on Glaukos to $120 From $126, Keeps Buy Rating	MT
25-07-31	UBS Adjusts Price Target on Glaukos Corp to $134 From $125, Maintains Buy Rating	MT
25-07-30	Glaukos beats Q2 sales estimates, raises 2025 guidance	RE
25-05-06	Analyst recommendations: Block, Chevron, Fortinet, Skechers, Palantir…
25-05-01	Truist Adjusts Price Target on Glaukos Corp to $135 From $140, Maintains Buy Rating	MT
25-04-11	Truist Cuts Price Target on Glaukos to $140 From $185, Keeps Buy Rating	MT
25-02-19	Mizuho Upgrades Glaukos Corp to Outperform From Neutral, Adjusts Price Target to $200 From $140	MT
24-12-31	Stifel Adjusts Price Target on Glaukos to $175 From $153, Keeps Buy Rating	MT
24-12-18	Truist Securities Adjusts Price Target on Glaukos to $185 From $152, Keeps Buy Rating	MT
24-12-11	Citigroup Upgrades Glaukos to Buy From Neutral, Raises Price Target to $162 From $132	MT
24-12-06	UBS Initiates Glaukos at Buy With $182 Price Target	MT
24-12-02	Morgan Stanley Downgrades Glaukos Corp to Underweight	MT
24-10-14	Truist Raises Price Target on Glaukos to $152 From $145, Maintains Buy Rating	MT

More recommendations

Medical Devices & Implants

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
GLAUKOS CORPORATION			+15.71%
STRYKER CORPORATION			+39.36%
SMITH & NEPHEW PLC			+22.73%
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.			+50.14%
DOUBLE MEDICAL TECHNOLOGY INC.	-	-	+30.55%
INSPIRE MEDICAL SYSTEMS, INC.			-10.84%
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.			+49.85%
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-	-	-
Average			+28.21%
Weighted average by Cap.			+35.71%